Gene editing has advanced at a remarkable pace, promising new treatments for genetic diseases, cancer and other complex conditions.
Yet as therapeutic approaches become more sophisticated, manufacturing the DNA components needed to develop and deliver these therapies has emerged as a critical challenge.
Traditional DNA production methods can struggle to meet the demands of next-generation applications that require longer, higher-quality genetic constructs at scale.
In response, synthetic DNA specialist 4basebio has launched a new high-performance enzymatic single-stranded DNA (ssDNA) platform capable of producing constructs up to 10,000 nucleotides long.
In this Q&A, CEO Amy Walker (pictured) discusses why DNA manufacturing has become one of the industry's most important bottlenecks, how cell-free enzymatic production could accelerate innovation in gene editing, where biopharma is placing its bets on emerging therapies and what these advances could mean for patients with rare and paediatric diseases.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.